Table 4.
Associations Between Clinicopathologic Characteristics and PFS in Breast Cancer Skeletal Metastases Patients
| Variables | Number of Patients | Number of Events | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |||
| Age (years) | ||||||
| <55 | 96 | 30 | 1 | / | ||
| ≥55 | 116 | 50 | 1.344(0.853–2.117) | 0.202 | / | / |
| Histological grade | ||||||
| I–II | 76 | 19 | 1 | 1 | ||
| III–IV | 136 | 61 | 1.883(1.125–3.153) | 0.016 | 1.328(0.738–2.389) | 0.344 |
| ER status | ||||||
| (-) | 92 | 44 | 1 | 1 | ||
| (+) | 120 | 36 | 0.609(0.392–0.946) | 0.027 | 0.601(0.384–0.941) | 0.026 |
| PR status | ||||||
| (-) | 146 | 59 | 1 | / | ||
| (+) | 66 | 21 | 0.766(0.465–1.261) | 0.295 | / | / |
| HER2 status | ||||||
| (-) | 146 | 59 | 1 | / | ||
| (+) | 66 | 21 | 0.981(0.626–1.535) | 0.931 | / | / |
| Ki-67 | ||||||
| <14% | 71 | 32 | 1 | / | ||
| ≥14% | 141 | 48 | 0.865(0.552–1.356) | 0.527 | / | / |
| The number of involved sites of visceral metastases | ||||||
| 0 | 106 | 39 | 1 | / | ||
| 1 | 20 | 12 | 1.748(0.915–3.342) | 0.091 | / | |
| >1 | 86 | 29 | 0.818(0.503–1.330) | 0.418 | / | / |
| The number of involved sites of bone metastases | ||||||
| 1 | 101 | 30 | 1 | 1 | ||
| 2–3 | 90 | 37 | 1.433(0.885–2.321) | 0.143 | 1.570(0.902–2.731) | 0.110 |
| >3 | 21 | 13 | 2.659(1.383–5.110) | 0.003 | 2.047(1.003–4.179) | 0.049 |
| Type of surgery | ||||||
| Breast-conserving surgery | 86 | 30 | 1 | / | ||
| Radical mastectomy | 126 | 50 | 1.402(0.890–2.206) | 0.145 | / | / |
| Radiotherapy to the primary site | ||||||
| No | 71 | 23 | 1 | / | ||
| Yes | 141 | 57 | 1.079(0.664–1.752) | 0.759 | / | / |
| Endocrine therapy | ||||||
| No | 172 | 67 | 1 | / | ||
| Yes | 40 | 13 | 0.712(0.393–1.291) | 0.264 | / | / |
| Targeted therapy | ||||||
| No | 97 | 40 | 1 | / | ||
| Yes | 115 | 40 | 0.674(0.434–1.046) | 0.079 | / | / |
| Bisphosphonate treatment | ||||||
| No | 53 | 21 | 1 | / | ||
| Yes | 159 | 59 | 0.896(0.544–1.475) | 0.666 | / | / |
| Surgery to the affected bone | ||||||
| No | 165 | 63 | 1 | / | ||
| Yes | 47 | 17 | 1.009(0.590–1.726) | 0.972 | / | / |
| Radiotherapy to the affected bone | ||||||
| No | 139 | 62 | 1 | 1 | ||
| Yes | 73 | 18 | 0.498(0.294–0.842) | 0.009 | 0.458(0.264–0.794) | 0.005 |
| NLR | ||||||
| <2.48 | 90 | 21 | 1 | 1 | ||
| ≥2.48 | 122 | 59 | 2.667(1.619–4.394) | <0.0001 | 1.971(1.169–3.321) | 0.011 |
| LMR | ||||||
| <3.43 | 120 | 36 | 1 | 1 | ||
| ≥3.43 | 92 | 44 | 0.376(0.235–0.601) | <0.0001 | 0.501(0.305–0.823) | 0.006 |
| CAR | ||||||
| <0.34 | 168 | 56 | 1 | 1 | ||
| ≥0.34 | 44 | 24 | 1.675(1.038–2.702) | 0.035 | 1.297(0.791–2.127) | 0.302 |
Note: Bold text: P value < 0.05.
Abbreviations: PFS, progression-free survival; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; CI, confidence interval; T, tumor; N, lymph node involvement; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; CAR, C-reactive protein/albumin ratio.